We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tristel Plc | LSE:TSTL | London | Ordinary Share | GB00B07RVT99 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
15.00 | 3.23% | 480.00 | 460.00 | 480.00 | 470.00 | 465.00 | 465.00 | 33,518 | 16:35:01 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 36.01M | 4.46M | 0.0941 | 49.95 | 222.78M |
Date | Subject | Author | Discuss |
---|---|---|---|
18/10/2021 15:59 | Webcast due to start in ½ hour The presentation is on the website | piedro | |
18/10/2021 15:01 | Thoroughly expecting growth to return for the next few years.Backlog of surgeryUK stock build has run back to normalOpportunities to expand in big markets - US, Canada, Far East etc | paulisi | |
18/10/2021 09:02 | I've been patiently waiting over 18 months for a routine endoscopy at my local NHS ENT Clinic and there must be thousands of others like me around the country given the record waiting lists. It's hardly surprising that a company that relies on this and related markets has not grown in the pandemic. Give us a break please! | gre | |
18/10/2021 08:54 | I can understand some pressure on the results due to the COVID impact on elective surgery activity. What I can't understand is how you design a share based remuneration system that doubles the cost in a year when PBT falls by 44%. And I do wish they'd stop the nonsense of disclosing results where they try to treat share based payments as an exceptional cost. It's not, its part of the cost base of the business. | cpgrang | |
18/10/2021 08:36 | Very disappointing for a growth stock with no growth. | paulisi | |
18/10/2021 08:29 | Market not viewing the finals so optimistically atm; new 1 yr low. | wad collector | |
18/10/2021 07:45 | Digging in to the detail not too bad with the long term outlook looking positive. Finally a date for FDA decision it will be close to ten years unbelievable | best1467 | |
18/10/2021 07:41 | Results very much as expected. Future prospects look good with end in sight to lengthy US approval process and NHS stock run down after Brexit. Onwards and upwards. | gre | |
18/10/2021 07:35 | FY results as signalled at the July TU then. Not pretty but the share price has already reflected those numbers by falling 30% and the outlook is much brighter - and future sales will be against soft comparatives: "During the first quarter of the current financial year, we can see that patient examinations in most of our markets are increasing. Furthermore, in the UK, the NHS has almost used up the stock of Tristel products it purchased in late 2020 to safeguard against a disorderly Brexit, and this supply overhang will soon be removed. For the first time in eighteen months, we are confident that our normal predictable pattern of business has resumed." | melody9999 | |
17/10/2021 10:08 | Finals out tomorrow. | wad collector | |
13/10/2021 10:36 | From the 21/07/2021 Trading Update "In April, sales for the year ending 30 June were anticipated to be £31m and pre-tax profit (before share-based payments) to be no less than £5m. As the fourth quarter progressed, demand for the device-based products accelerated as hospital out-patient departments gradually returned to pre-pandemic levels of activity. Surface disinfectant product sales have continued to grow. It is expected that the upturn in sales activity, combined with a gross margin maintained at 80% and tight control over operating costs, will translate into sales of £31m (2020: £31.7m) and pre-tax profit (before share-based payments and the exceptional item explained below) of £5.5m (2020: £7.1m) for the year." The April update contained the profit warning Now at least PBT has improved from "no less than £5m" to "of £5.5m" Re: "medical device company focussed upon women's health" ... "Tristel will take a conservative approach to the carrying value of the investment, totalling £0.8m, and fully impair this in the financial year just ended." - It will be interesting to see where it will be "impaired" in the accounts | piedro | |
12/10/2021 11:01 | That's me finally trailed out for a moderate profit as for my style it's broken trend to the downside. At least I don't have the gap risk if they disappoint with next weeks planned news. | davr0s | |
28/9/2021 11:30 | FWIW ... 4 Reasons You’re Disinfecting Improperly By J. Darrel Hicks September 27, 2021 | piedro | |
25/9/2021 11:49 | I see huge growth potential in next 2-3 years with access to India, China and North America plus an established European market.Where the company goes after that is unknown. Unless they develop new products or bolt on acquisitions, they would be stagnating and primed for a takeover. | paulisi | |
21/7/2021 11:20 | Melody above is in tune with my reaction too. I think by the time the divi comes round it will be back to 650p. The initial fall has tempered somewhat perhaps because its somewhat wooly nature of its wording saw the market take a shears to the share price I am continuing to hold as we can see hospitals are returning yo normal and it was this uncertainty which put the share price to date in a sick Bay after it reached the dizzy heights of 700p. Glad the company have come clean today and the situation is nothing like the market reaction suggests. | mach100 | |
21/7/2021 10:50 | Good for you APAD. You've picked out the positive in the TU. Now I feel better. Thank you. Piedro | piedro | |
21/7/2021 09:46 | Hey! We bought a stake in a company that we have now written off, but it gave us loads of AI. Yeah Right! apad | apad | |
21/7/2021 09:29 | What a strange Trading Update - it smacks of a profit warning "Outlook Towards the end of the financial year the Company witnessed an increase in hospital admissions and patient examinations. The Company is confident that sales and profits growth will resume this year and the investments made in people, systems and new market registrations will lay the foundation for strong growth in the years ahead." Basically, they have made a load of investments in a slow market. I am getting reminders of 2011, (was it?), when the market did not meet their expectations. This time, will it uphold their confidence? Sorry for my nervousness, the road has been uphill and bumpy. And are they keeping back the surprise for October? "A more detailed update on the progress of the USA FDA submission for Duo ULT for ultrasound probe disinfection and the commercial development plan for North America will be provided with the final results in October 2021." The share price feels it. AIMHO and GLA | piedro | |
21/7/2021 09:13 | That's good - I love triple tops as that means it's just consolidating in a basing pattern | davr0s | |
21/7/2021 09:06 | Looks triple toppy | volsung | |
21/7/2021 08:35 | Surprised with the market reaction - on or above forecast. | paulisi | |
21/7/2021 08:30 | Yeah seemed ok. But very early trading today so let's see where it ends up in a few days time | davr0s | |
15/7/2021 08:49 | FYI, NEWS RELEASE 11-JUL-2021 New study shows that silver foil could reduce the risk of infection in hospitals EUROPEAN SOCIETY OF CLINICAL MICROBIOLOGY AND INFECTIOUS DISEASES | piedro | |
12/7/2021 12:11 | The greed for money is one argument and what is correct is another. Which is what? | piedro |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions